Loading...

CTMX - CytomX Therapeutics, Inc.

Analyst Coverage Initiated Signal for 06-24-2022
Analyst Coverage Initiated: CTMX rating Outperform by BMO Capital Markets
Price Target: $9


Loading Chart CTMX

Stock Signal Information


Signal

Analyst Coverage Initiated: CTMX rating Outperform by BMO Capital Markets
Price Target: $9
Report Date: 06-24-2022
Symbol: CTMX - CytomX Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Initiated: CTMX rating Outperform by BMO Capital Markets
Price Target: $9

  CTMX Technical Analysis

Company Contact

CytomX Therapeutics, Inc. (CTMX)
151 Oyster Point Blvd Ste 400
South San Francisco, CALIFORNIA 94080
Phone: 16505153185
Website: http://www.cytomx.com
CEO: DR. Sean McCarthy

CTMX, CytomX Therapeutics, Inc.

CTMX CytomX Therapeutics, Inc. Logo Image

NASDAQ, Nasdaq Global Select


Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.